Levodopa/Benserazid Ratiopharm (Benserazide, Levodopa)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier and is converted into dopamine within the central nervous system. This restores deficient dopaminergic signaling in Parkinson's disease, which is essential for controlling movement and coordination.

The appropriate dose of Levodopa/Benserazid is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing side effects.

The safety of Levodopa/Benserazid in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the team will provide pricing, availability, shipping details, and any necessary import documentation.

Levodopa/Benserazid is considered the most effective symptomatic therapy for Parkinson's disease because it directly replenishes brain dopamine. Compared with dopamine agonists, it often provides stronger motor improvement but may have a higher risk of motor complications such as dyskinesia over long‑term use.

Store Levodopa/Benserazid tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Levodopa/Benserazid is taken orally, usually with a glass of water. It may be administered with or without food, but high‑protein meals can interfere with absorption, so clinicians often advise spacing the dose away from protein‑rich meals.

Serious risks include neuroleptic malignant syndrome, severe psychiatric disturbances such as hallucinations or psychosis, and cardiac arrhythmias. Patients should be monitored closely for any sudden changes in mental status, temperature, or heart rhythm, and seek immediate medical attention if these occur.

Levodopa/Benserazid is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients. It should also be avoided in individuals taking non‑selective MAO inhibitors without an appropriate washout period, and in patients with narrow‑angle glaucoma or uncontrolled cardiac disease.